SELLAS Life Sciences Stock Quote SLS - Stock Price, News, Charts, Message Board, Trades

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
SELLAS Life Sciences Group Inc (SLS) Quote

SELLAS Life Sciences Group Inc (SLS)

1.14

0.02

(1.79%)

Closed July 03 4:00PM

Delayed by 15 minutes

1.1405

0.0005

( 0.04% )

Pre Market: 9:02AM

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Current Price

1.1405

Bid

1.14

Ask

1.19

Volume

1,572

0.00 Day's Range 0.00

0.4986 52 Week Range 1.914

Market Cap

Previous Close

1.14

Open

-

Last Trade

Last Trade Time

08:41:55

Financial Volume

-

VWAP

-

Average Volume (3m)

1,263,186

Shares Outstanding

57,754,928

Dividend Yield

-

PE Ratio

-1.76

Earnings Per Share (EPS)

-0.65

Revenue

-

Net Profit

-37.34M

SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax. SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.sellaslifesciences.com/home/default.aspx

Headquarters

Wilmington, Delaware, USA

Founded

1970

SELLAS Life Sciences Group Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SLS. The last closing price for SELLAS Life Sciences was $1.14. Over the last year, SELLAS Life Sciences shares have traded in a share price range of $ 0.4986 to $ 1.914.

SELLAS Life Sciences currently has 57,754,928 shares outstanding. The market capitalization of SELLAS Life Sciences is $65.84 million. SELLAS Life Sciences has a price to earnings ratio (PE ratio) of -1.76.

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0595	-4.95833333333	1.2	1.2	1.1	472855	1.146375	CS
4	-0.2995	-20.7986111111	1.44	1.7	0.81	1442034	1.27860138	CS
12	-0.2795	-19.6830985915	1.42	1.72	0.81	1263186	1.34757992	CS
26	0.5405	90.0833333333	0.6	1.72	0.4986	1350440	1.12187255	CS
52	-0.4195	-26.891025641	1.56	1.914	0.4986	916802	1.11633534	CS
156	-7.8595	-87.3277777778	9	10.82	0.4986	467478	2.14030773	CS
260	0.8995	373.236514523	0.241	19.38	0.11	2068660	2.25798038	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CYNCYNGN Inc	$ 4.70 (8,652.33%)	3.85k
QLGNQualigen Therapeutics Inc	$ 0.398 (126.91%)	58.54M
ZAPPZapp Electric Vehicles Group Ltd	$ 4.23 (55.51%)	15.07M
KOSSKoss Corporation	$ 14.43 (35.75%)	8.24M
MICSSinging Machine Company Inc	$ 1.56 (34.48%)	10.2M
FKWLFranklin Wireless Corporation	$ 2.81 (-20.85%)	5
JEWLAdamas One Corporation	$ 0.372 (-19.39%)	261.67k
ARTWArts Way Manufacturing Co Inc	$ 1.30 (-18.75%)	1
BTFXValkyrie Bitcoin Futures Leveraged Strategy ETF	$ 22.73 (-16.09%)	3.85k
ELWSEarlyworks Co Ltd	$ 1.95 (-14.85%)	74
QLGNQualigen Therapeutics Inc	$ 0.398 (126.91%)	58.54M
MAXNMaxeon Solar Technologies Ltd	$ 0.191 (10.02%)	49.24M
ZAPPZapp Electric Vehicles Group Ltd	$ 4.23 (55.51%)	15.07M
STSSSharps Technology Inc	$ 0.273 (18.70%)	14.58M
MICSSinging Machine Company Inc	$ 1.56 (34.48%)	10.2M

Boxsterfan

Boxsterfan 1 week ago

https://duediligencegenie.com/wp-content/uploads/2024/05/Sellas-Life-Sciences.pdf This should be sticky posted.

TTsr

TTsr 3 weeks ago

The longer this goes, it is gonna POP… BP gotta know what SLS has, 2,assets that are extending OS 3 to 5X.

govprs

govprs 3 weeks ago

https://www.barchart.com/stocks/quotes/SLS/opinion

peterus

peterus 1 month ago

harry crumb

harry crumb 2 months ago

Moneymaker here folks$$$$$

TIMGZ

TIMGZ 2 months ago

VERY OBSERVANT, THANK YOU FOR THE ANALOGY! TOMORROW MIGHT MAKE A DIFFERENCE****WE SHALL SEE

harry crumb

harry crumb 2 months ago

Lol, oh there are still a stash of those, in the 20’s! $$$$$!!

Monksdream

Monksdream 2 months ago

You should have taken CVNA which go to da moon
Now back to getting richer

harry crumb

harry crumb 2 months ago

Huge move up could happen anytime, lottery play could go to da moon! $$$$$

TTsr

TTsr 2 months ago

With positive REGAL results this will eventually explode

TTsr

TTsr 2 months ago

According to the charters, which I am not, 9 million volume traded so far today - largest volume day in 3 years - 6 of the 9 million sold short

Monksdream

Monksdream 2 months ago

TIMGZ

TIMGZ 2 months ago

SURPRISED SLS IS NOT MOVING**** WAS AN EXCELLENT NEWS***** HOW ARE U *******

YOU ARE NOT AS FREQUENT AS BEFORE , YOU MUST BE SOMEWHERE ELSE***SHARE THE KNOWLEDGE

harry crumb

harry crumb 2 months ago

TheFinalCD

TheFinalCD 2 months ago

1.27 SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level $SLS https://t.co/bQBsEQo7jc— Health Stocks News (@health_stocks) May 1, 2024

harry crumb

harry crumb 2 months ago

Somebody shorted the sh.. out of this today, pretty risky at this point, but whatever….

govprs

govprs 3 months ago

Yahoo finance add sls and review of the conversations tab.

peterus

peterus 3 months ago

you have a link ?

govprs

govprs 3 months ago

On yahoo they are talking 4 min.

harry crumb

harry crumb 3 months ago

Agree, might see 1.70’s again, worth the risk with a stop limit on shares purchased at 1$ or more

peterus

peterus 3 months ago

TTsr

TTsr 3 months ago

I believe it’s gonna before EOM… pr stated idmc scheduled ‘by’ EOM…

peterus

peterus 3 months ago

yup think next month data phase3 end april ... should see 1.50s before data

harry crumb

harry crumb 3 months ago

Maybe another pop to 1.60

Monksdream

Monksdream 3 months ago

SLS 10Q due 3/22

Monksdream

Monksdream 4 months ago

harry crumb

harry crumb 4 months ago

Hit an run with this one

harry crumb

harry crumb 5 months ago

No way, lotto play here. This is nothing but risk

CarlCarlMcB

CarlCarlMcB 5 months ago

Let’s go $$$$$ reeling $$$$$$

harry crumb

harry crumb 6 months ago

Monksdream

Monksdream 6 months ago

SLS new 52 week low

willlbone

willlbone 6 months ago

CarlCarlMcB

CarlCarlMcB 6 months ago

Merry Christmas $$$$$

harry crumb

harry crumb 6 months ago

Doubt it, insiders just sold shares!

drkazmd65

drkazmd65 6 months ago

Rumor mill over on Stocktwits is that STELLAS is about to receive Orphan Drug status for their T-cell lymphoma treatment. No PR out yet but,.... Dated today,...

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=977523

harry crumb

harry crumb 8 months ago

Climbing back up

Monksdream

Monksdream 9 months ago

SLS new 52 week low

CarlCarlMcB

CarlCarlMcB 9 months ago

Sex always makes money! Lol

weedtrader420

weedtrader420 9 months ago

SLS FDA NEWS WOOHOOOOOO WOOHOOOOOO

Monksdream

Monksdream 9 months ago

harry crumb

harry crumb 1 year ago

After that dilution it’l double in price, always does

harry crumb

harry crumb 1 year ago

Breakout coming, this science could be a game changer

TTsr

TTsr 1 year ago

Fingers crossed! Still an unknown, to us, but after the first IDMC & positive sentiment from Tuesday’s KOL TC it’s hard to imagine GPS not achieving its P3 primary endpoints!

harry crumb

harry crumb 1 year ago

News coming? It’s rippn

harry crumb

harry crumb 1 year ago

3.09 trade! Lmao, mm’s will do anything to get cheapies. This ticker could be a huge play moving forwsrd $$$

harry crumb

harry crumb 1 year ago

harry crumb

harry crumb 1 year ago

Added to the stash

TTsr

TTsr 2 years ago

“Following a prespecified review of unblinded data by the IDMC in accordance with its charter, its recommendation to continue the REGAL study as is, and with trial conduct and integrity intact, is outstanding news.” This quote was from the Sellas PR… does any know when the next ‘schedule’ IDMC review is? Or is that info not available to the public?

harry crumb

harry crumb 2 years ago

Back in today for the ride

harry crumb

harry crumb 2 years ago

Wow glad we sold, held a few free ones, big hit today on the PR

SELLAS Life Sciences

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions